Abstract
The systemic nature of the inflammatory processes in psoriasis is now widely accepted. It is known that the IL-23/ Th-17 axis plays a pivotal role in the development of skin and joint symptoms, which immune processes overlap with the pathways involved in the pathogenesis of cardiometabolic comorbidities at several points. IL-17 inhibitor biological therapies are frontline treatments for moderate-to-severe psoriasis and have also been the focus of interest in recent years because of their potential effects on comorbidities. In this review we aim to describe the processes of the IL-23/Th-17 axis associated with cardiometabolic pathologies and the effect of IL-17 inhibitors on these comorbidities through international data and studies conducted at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
